Seefinish Insights Trends news knowledge Discovery

ReadR

ReadR

ReadR: Read and Share all content, headlines, news and trends results with Seefinish ReadR App.

Discover Content : Trends

Discover real-time trending topics, news headlines, twitter trends, google trends, hashtags, and content from different countries in the world.

Search Here

Navigation Tabs

Top Countries

Select Country:🌐

Worldwide 🌍 | Nigeria 🇳🇬 | South Africa 🇿🇦 | Kenya 🇰🇪 |Brazil 🇧🇷| Canada 🇨🇦 | United Kingdom 🇬🇧| United States 🇺🇸

See all other continents, locations, categories and associated headlines or trending informations here using

America:
Brazil 🇧🇷| Canada 🇨🇦 | United States 🇺🇸

Africa:
Algeria 🇩🇿 | Egypt 🇪🇬 | Ghana 🇬🇭 | Kenya 🇰🇪 |Morocco 🇲🇦| Nigeria 🇳🇬 | South Africa 🇿🇦 | Zambia 🇿🇲 |

Middle East:
| Israel 🇮🇱|kuwait 🇰🇼 |Saudi Arabia 🇸🇦 |Turkey 🇹🇷| Cyprus 🇨🇾 |

Europe:
Finland 🇫🇮|France 🇫🇷| Hungary 🇭🇺 |Germany 🇩🇪| Italy 🇮🇹 | Poland | Slovakia 🇸🇰 | Switzerland 🇨🇭 | Spain | United Kingdom 🇬🇧

Australia/Oceania: 🌐
Australia 🇦🇺|New Zealand 🇦🇺

Asia:
China 🇨🇳 | Japan 🇯🇵| India 🇮🇳| Malaysia 🇲🇾| Philippines 🇵🇭 | Singapore 🇸🇬 |Thailand 🇹🇭 |

Show more
Show less

Headline : European drug regulator rejects Alzheimers treatment Leqembi from Biogen, Eisai

Read more from the original article on here at www.cnbc.com.






Tags : #european #drug #regulator #rejects #alzheimers #treatment #leqembi #biogen #eisai


No. of Paragraph 17

European drug regulators on Friday rejected the Alzheimer's treatment Leqembi from Biogen and Eisai, creating another hurdle for the companies as they scramble to boost uptake of the therapy in the U.S. 

The European Commission, the European Union's executive body, has a final say in Leqembi's approval. But it almost always follows the drug regulator's recommendations. 

In a statement, Eisai said, it is "extremely disappointed" by the regulator's negative recommendation. The company added that it will seek a reexamination of the decision.

Shares of Biogen fell more than 6% on Friday. Japanese drugmaker Eisai's stock was essentially flat. 

Read more from the original article on here at www.cnbc.com.


Related Headlines : European drug regulator rejects Alzheimers treatment Leqembi from Biogen, Eisai (in Google.com):

Hello, below you have a "Web" tab to read more content and an "Image" tab to get related pictures

Example : Trends, Country, News, Jobs, Scholarships, Investment, Business, Politics, Adverts, Fashion, Events, Technology and more.